1. Market Research
  2. > Pharmaceutical Market Trends
  3. > High Triglyceridemia - Pipeline Review, H1 2015

High Triglyceridemia - Pipeline Review, H1 2015

  • January 2015
  • -
  • Global Markets Direct
  • -
  • 105 pages

High Triglyceridemia - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘High Triglyceridemia - Pipeline Review, H1 2015’, provides an overview of the High Triglyceridemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for High Triglyceridemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High Triglyceridemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of High Triglyceridemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for High Triglyceridemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the High Triglyceridemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the High Triglyceridemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for High Triglyceridemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding High Triglyceridemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

High Triglyceridemia - Pipeline Review, H1 2015
Table of Contents
Introduction 8
Global Markets Direct Report Coverage 8
High Triglyceridemia Overview 9
Therapeutics Development 10
Pipeline Products for High Triglyceridemia - Overview 10
Pipeline Products for High Triglyceridemia - Comparative Analysis 11
High Triglyceridemia - Therapeutics under Development by Companies 12
High Triglyceridemia - Therapeutics under Investigation by Universities/Institutes 15
High Triglyceridemia - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
High Triglyceridemia - Products under Development by Companies 19
High Triglyceridemia - Products under Investigation by Universities/Institutes 21
High Triglyceridemia - Companies Involved in Therapeutics Development 22
Acasti Pharma Inc. 22
Actavis plc 23
Alnylam Pharmaceuticals, Inc. 24
Arisaph Pharmaceuticals, Inc. 25
Astellas Pharma Inc. 26
AstraZeneca PLC 27
BASF SE 28
Cardax Pharmaceuticals, Inc. 29
Catabasis Pharmaceuticals, Inc. 30
Essentialis, Inc. 31
Isis Pharmaceuticals, Inc. 32
Jeil Pharmaceutical Co., Ltd. 33
Novartis AG 34
Pharmena SA 35
Poxel SA 36
Tekmira Pharmaceuticals Corp. 37
Thetis Pharmaceuticals LLC 38
High Triglyceridemia - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
ALN-AC3 - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
ALN-ANG - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
ARI-3037MO - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
AS-1708727 - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
bezafibrate ER - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
BioE-1115 - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
CAT-2003 - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
CDX-085 - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
diazoxide choline CR - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
ISIS-APOCIIIRx - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
MAT-9001 - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
NKPL-66 - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
pradigastat sodium - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
PRC-4016 - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
Small Molecule for Hypertriglyceridaemia - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
Small Molecule to Agonize Farnesoid X Receptor for Metabolic Disorders, Cardiovascular and Gastrointestinal Disorders - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
Small Molecules for Dyslipidemia and Hypertriglyceridemia - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
Synthetic Peptides for Dyslipidemic and Vascular Disorders - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
TKM-HTG - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
TP-101 - Drug Profile 71
Product Description 71
Mechanism of Action 71
RandD Progress 71
TP-110 - Drug Profile 72
Product Description 72
Mechanism of Action 72
RandD Progress 72
TP-252 - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
TP-8252 - Drug Profile 76
Product Description 76
Mechanism of Action 76
RandD Progress 76
TRIA-662 - Drug Profile 78
Product Description 78
Mechanism of Action 78
RandD Progress 78
High Triglyceridemia - Recent Pipeline Updates 80
High Triglyceridemia - Dormant Projects 94
High Triglyceridemia - Discontinued Products 95
High Triglyceridemia - Product Development Milestones 96
Featured News and Press Releases 96
Dec 23, 2014: Matinas BioPharma Provides Update on Clinical Development Program for MAT9001 Following FDA Feedback on IND Submission 96
Nov 12, 2014: Matinas BioPharma Commences Dosing in First Human Trial of Lead Product Candidate MAT9001 97
Nov 10, 2014: Matinas Biopharma Receives Notice of Allowance of U.S. Patent for MAT9001 97
Oct 29, 2014: Matinas BioPharma Receives Authorization From Health Canada to Initiate Human Clinical Study of Lead Product Candidate MAT9001 98
Oct 20, 2014: Matinas BioPharma Submits Investigational New Drug Application for Lead Product Candidate MAT9001 for the Treatment of Severe Hypertriglyceridemia 99
Sep 30, 2014: Matinas BioPharma to Present at the 13th Annual BIO Investor Forum on Wednesday, October 8, 2014 99
Sep 30, 2014: Acasti Announces Positive Top-Line Pharmacokinetic Results 100
Sep 29, 2014: Acasti Reports Successful CaPre Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides and Non-HDL-C 101
Sep 04, 2014: Matinas BioPharma to Present at Three Investor Conferences in September 102
Sep 02, 2014: Isis Pharmaceuticals Presents Data On ISIS-APOCIIIRX At European Society of Cardiology Congress 2014 103
Appendix 104
Methodology 104
Coverage 104
Secondary Research 104
Primary Research 104
Expert Panel Validation 104
Contact Us 105
Disclaimer 105

List of Tables

Number of Products under Development for High Triglyceridemia, H1 2015 10
Number of Products under Development for High Triglyceridemia - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Development by Companies, H1 2015 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2015 15
Comparative Analysis by Late Stage Development, H1 2015 16
Comparative Analysis by Clinical Stage Development, H1 2015 17
Comparative Analysis by Early Stage Development, H1 2015 18
Products under Development by Companies, H1 2015 19
Products under Development by Companies, H1 2015 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2015 21
High Triglyceridemia - Pipeline by Acasti Pharma Inc., H1 2015 22
High Triglyceridemia - Pipeline by Actavis plc, H1 2015 23
High Triglyceridemia - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015 24
High Triglyceridemia - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2015 25
High Triglyceridemia - Pipeline by Astellas Pharma Inc., H1 2015 26
High Triglyceridemia - Pipeline by AstraZeneca PLC, H1 2015 27
High Triglyceridemia - Pipeline by BASF SE, H1 2015 28
High Triglyceridemia - Pipeline by Cardax Pharmaceuticals, Inc., H1 2015 29
High Triglyceridemia - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2015 30
High Triglyceridemia - Pipeline by Essentialis, Inc., H1 2015 31
High Triglyceridemia - Pipeline by Isis Pharmaceuticals, Inc., H1 2015 32
High Triglyceridemia - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2015 33
High Triglyceridemia - Pipeline by Novartis AG, H1 2015 34
High Triglyceridemia - Pipeline by Pharmena SA, H1 2015 35
High Triglyceridemia - Pipeline by Poxel SA, H1 2015 36
High Triglyceridemia - Pipeline by Tekmira Pharmaceuticals Corp., H1 2015 37
High Triglyceridemia - Pipeline by Thetis Pharmaceuticals LLC, H1 2015 38
Assessment by Monotherapy Products, H1 2015 39
Number of Products by Stage and Target, H1 2015 41
Number of Products by Stage and Mechanism of Action, H1 2015 43
Number of Products by Stage and Route of Administration, H1 2015 45
Number of Products by Stage and Molecule Type, H1 2015 47
High Triglyceridemia Therapeutics - Recent Pipeline Updates, H1 2015 80
High Triglyceridemia - Dormant Projects, H1 2015 94
High Triglyceridemia - Discontinued Products, H1 2015 95

List of Figures

Number of Products under Development for High Triglyceridemia, H1 2015 10
Number of Products under Development for High Triglyceridemia - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 17
Comparative Analysis by Early Stage Products, H1 2015 18
Assessment by Monotherapy Products, H1 2015 39
Number of Products by Top 10 Targets, H1 2015 40
Number of Products by Stage and Top 10 Targets, H1 2015 40
Number of Products by Top 10 Mechanism of Actions, H1 2015 42
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 42
Number of Products by Top 10 Routes of Administration, H1 2015 44
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 45
Number of Products by Top 10 Molecule Types, H1 2015 46
Number of Products by Stage and Top 10 Molecule Types, H1 2015 47

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.